Skip to main content

Table 3 Summary of adverse events

From: The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China

Adverse event Niraparib monotherapy (n = 18) Niraparib combined therapy (n = 4)
Any grade Grade 3 or 4 Any grade Grade 3 or 4
Number of patients (percent)
Nausea 10 (55.6) 0 (0) 2 (50.0) 0 (0)
Thrombocytopenia 8 (44.4) 3 (16.7) 3 (75.0) 1 (25.0)
Anemia 6 (33.3) 1 (5.6) 3 (75.0) 1 (25.0)
Decreased appetite 6 (33.3) 0 (0) 1 (25.0) 0 (0)
Fatigue or asthenia 5 (27.8) 0 (0) 3 (75.0) 0 (0)
Constipation 5 (27.8) 0 (0) 1 (25.0) 0 (0)
Insomnia 5 (27.8) 0 (0) 0 (0) 0 (0)
Neutropenia 3 (16.7) 1 (5.6) 2 (50.0) 1 (25.0)
Vomiting 3 (16.7) 1 (5.6) 0 (0) 0 (0)
Dyspepsia 3 (16.7) 1 (5.6) 0 (0) 0 (0)
Headache 2 (11.1) 0 (0) 1 (25.0) 0 (0)
Abdominal distention 2 (11.1) 0 (0) 0 (0) 0 (0)
Dizziness 1 (5.6) 0 (0) 1 (25.0) 0 (0)
Dysgeusia 1 (5.6) 0 (0) 0 (0) 0 (0)
Back pain 1 (5.6) 0 (0) 0 (0) 0 (0)
Diarrhea 1 (5.6) 0 (0) 0 (0) 0 (0)
Maculopapular rash 1 (5.6) 0 (0) 0 (0) 0 (0)
Stomatitis 1 (5.6) 0 (0) 0 (0) 0 (0)
Dry mouth 1 (5.6) 0 (0) 0 (0) 0 (0)
Abdominal pain 0 (0) 0 (0) 1 (25.0) 0 (0)
Newly observed
 Leg swelling 1 (5.6) 0 (0) 0 (0) 0 (0)
Led to discontinuation of intervention 1 (5.6) 0 (0)
Led to dose reduction 3 (16.7) 1 (25.0)
Led to dose interruption 2 (11.1) 2 (50.0)
  1. Note: Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0